newsfilter
← Latest News
GlobeNewswire·

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2